Inspect the sources.

For many people with ADHD, stimulant medicines can reduce core ADHD symptoms compared with placebo. That is a population finding, not a promise that a particular medicine will help a particular person.

Prescription amphetamine treatment has been associated with an uncommon increased occurrence of psychotic symptoms compared with methylphenidate in a large observational study of young people. The events were uncommon in both groups. Association is not proof that amphetamine caused psychosis in any individual.

Stopping or reducing many antidepressants can be followed by discontinuation symptoms in a substantial minority of people. Estimates of how often this happens vary widely by study method. Withdrawal is not the same as addiction, and it is not automatically the same as relapse.

For many antidepressants, staged dose reduction is commonly recommended rather than abrupt cessation. Paradoxical.life does not provide an individual tapering schedule.

Some therapeutic stimulant regimens are commonly managed differently at cessation than many antidepressants. Rebound fatigue, mood change, appetite change or return of ADHD symptoms can still occur. This is not a rule that ADHD medicine can always be stopped immediately.

Some people taking SSRIs report that emotions become less intense — both the difficult ones and the ones they wanted to keep. That experience is documented in qualitative research. It is not universal.

ADHD and depression commonly co-occur. A person can have both. Treating one does not automatically resolve the other, and a later ADHD recognition does not mean an earlier depression diagnosis was simply wrong.

ADHD is associated, in some studies, with differences in interoception — the sensing of internal bodily signals. Findings are mixed and samples are often small.

One plausible possibility is that improved attentional discrimination gives some people more capacity to recognise internal signals that were already present. Current research supports interoceptive differences in ADHD and supports changes in attentional regulation with treatment. The complete pathway from stimulant treatment to improved interoceptive awareness has not been established.

Antidepressants and ADHD medicines are sometimes prescribed together. Combination is not automatically unsafe, and it is not automatically the cause of any later change. Overlapping effects on sleep, appetite, heart rate, anxiety and activation deserve a timeline, not a slogan.

An adverse-event report to the TGA documents a suspected relationship. It does not prove that a medicine caused an event, and DAEN counts are not incidence rates.

Autistic burnout is described by autistic adults as chronic exhaustion, loss of skills, and reduced sensory tolerance after prolonged stress and masking. It is a lived-experience construct with growing qualitative research. It is not a medication side-effect by definition, and it can be mistaken for, or overlap with, depression, shutdown, or withdrawal.

ADHD and autism commonly co-occur. They were not formally allowed as co-diagnoses until DSM-5 (2013). Having one does not rule out the other, and treating one does not automatically treat the other.

Depression, anxiety, sleep disorders, OCD, trauma-related conditions, substance-use problems and eating disorders commonly co-occur with ADHD and/or autism. They may be separate, interacting, or both. A later developmental diagnosis does not mean the psychiatric diagnosis was imaginary.

Bipolar disorder, borderline personality disorder and schizophrenia-spectrum disorders can share surface features with ADHD, autism, trauma or mood presentations. They can also coexist with neurodevelopmental conditions. They are not simply manifestations of neurodivergence. Correct differentiation can materially affect treatment.

Diagnostic overshadowing is the tendency to attribute symptoms automatically to an existing diagnosis, making another condition harder to recognise. The original experimental literature concerned intellectual disability. The same mechanism is clinically relevant when ADHD, autism or a psychiatric label becomes a ceiling on curiosity.

Different parts of a person's profile are often recognised at different points in life. In children with both ADHD and autism, those whose ADHD was identified first have been observed to receive an autism diagnosis later. A later diagnosis does not automatically invalidate an earlier one.

In Australia, ADHD assessment is constrained by clinician availability, waiting time, out-of-pocket cost, a thin public adult pathway, and regional gaps. Recognition is growing faster than the systems built to assess it.

Rising ADHD diagnosis and medicine dispensing in Australia are evidence of rising recognised demand. They are not, by themselves, evidence that underlying ADHD prevalence has increased by the same factor. Prevalence, recognition, diagnosis and service demand are different quantities.

Historically, ADHD assessment and stimulant treatment in Australia have relied heavily on psychiatrists and paediatricians. Pathways are now changing in some jurisdictions. In Western Australia, specially trained GPs can now assess, diagnose and treat suitable ADHD patients from age 10, while complex presentations continue to require specialist involvement.

More people being recognised is observable. More people seeking assessment is observable. More people receiving ADHD medication is observable. A sudden increase in the underlying prevalence of ADHD since 2020 is not currently established.

The National Disability Insurance Scheme Amendment (Securing the NDIS for Future Generations) Act 2026 is law. It passed the Senate on 18 August 2026, both houses on 19 August, and received Royal Assent on 20 August as Act No. 66 of 2026. It changes access, planning, funding instruments, permanence, other-scheme consideration, fraud powers, pricing and automation.

The department’s FAQ for the Act states that children aged eight and under with developmental delay and/or autism and low to moderate support needs will no longer be eligible for the NDIS, and that those children will be supported by Thriving Kids. Children with permanent and significant disability, and those in that age group with substantially reduced functional capacity, remain eligible. Access-criteria changes begin 1 January 2028.

Under the department’s FAQ, social, civic and community participation budgets are reduced by 50 per cent, and capacity-building daily-activity budgets by 10 per cent, as plans are renewed or reassessed. The government says essential daily-living supports and 24-hour disability-related care will not change. New plans and reassessments from 1 October 2026; other participants from 1 February 2027.

The Act still lets the Minister reduce funding for specified groups of supports. House amendments confined determinations to social, community and civic participation and/or capacity-building daily activities, and required them to name which plans they apply to. A later Senate amendment lets people who need continuous 24-hour care apply for a plan variation within 90 days. That pathway is a subset remedy, not a general exemption.

The Act names Thriving Kids as the receiving program for children aged eight and under with developmental delay and/or autism and low to moderate support needs. The same department still describes Thriving Kids service design as underway with states and territories, and the Thriving Kids page (updated 31 August 2026) does not publish a complete service catalogue or a worked interface with 2028 NDIS eligibility. A named program is not yet a specified substitute.

Journalism and advocacy have reported that around 145,000 autistic people could lose NDIS autism support, and that more than 240,000 participants could be shifted off the scheme after new eligibility rules. The department’s FAQ does not publish those figures. They are projections about a future process, not a completed removal.

The Act expands NDIS fraud and integrity powers: enrolment and registration, kickback offences, records retention, shorter claim windows, conflict-of-interest rules for plan management, investigative capability and whistleblower protections. Criticising access cuts, budget resets or an unfinished receiving system is not the same as opposing fraud enforcement. Those are different objects.

National Legal Aid’s June 2026 submission on the introduced bill warned that it would narrow access, constrain reassessment, raise evidentiary barriers, permit funding reductions by delegated instrument, and weaken practical review. Some of those points were later narrowed by amendment. Some were not. The submission is evidence about the introduced text, not a silent description of the Act as passed.

The House agreed to 18 government and 12 crossbench amendments on 1 July 2026. The Senate agreed to 32 government amendments on 18 August 2026 and passed the Bill. The House agreed to the Senate amendments the next day. The final law is not the May text.

The Bills Digest of the introduced bill records a proposed definition of functional capacity that assesses the ability to undertake an activity without assistance from other people, assistive technology or modifications, and in a context that excludes, as far as possible, the impact of environmental and personal circumstances. The government later said functional-capacity provisions were revised. New-framework planning is described as considering environmental factors. The public FAQ does not republish the final subsection.

From 1 January 2028, permanence for NDIS access requires ‘appropriate treatment’ subject to specified exceptions. The introduced digest records that treatment may still count as appropriate even where financial circumstances or geographical location restrict access. House amendments defined appropriate treatment as publicly funded care regularly undertaken in Australia and excluded restrictive practices. They did not remove the basic requirement.

From 27 August 2026, only a participant, nominee or child representative can request an unscheduled plan reassessment, on a significant and ongoing change. The NDIA has up to 90 days to decide. If no decision is made, the request is treated as refused, with review rights.

The Australian Human Rights Commission’s 28 May 2026 Senate submission raised the introduced bill’s potential to reduce access to supports, limit individualised decision-making and weaken safeguards, and asked that it not pass before PJCHR scrutiny. The Parliamentary Joint Committee on Human Rights examined the introduced bill in Report 7 of 2026. That is formal parliamentary scrutiny, not party commentary, and it addressed the introduced text.

Disability Representative Organisations do not speak with one throat, but a joint 1 June 2026 submission from twelve named organisations recommended that the introduced bill not proceed in that form. After Royal Assent, People with Disability Australia recorded that passing the law does not mean access assessment, treatment rules, automation, participation reforms and other instruments have been decided.

ADHD medication is not a set-and-forget prescription. Australian and NICE guidance expect review of benefit against adverse effects, with attention to sleep, appetite, heart rate and blood pressure, and — in children and adolescents — height and weight. Psychiatric symptoms that emerge or worsen belong in that review.

AuDHD is community language for autism and ADHD occurring together. It is not a separate DSM or ICD diagnosis with its own criteria. DSM-5 (2013) removed the earlier rule that had treated the two as mutually exclusive. Each condition still has to be assessed on its own terms. One does not automatically explain the other.

Clinical guidelines model ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity, with features present in more than one setting and with several signs in childhood, even if recognition comes later. Educational examples of those features are not a diagnostic test, a severity score, or a reason to start or stop a medicine.